WATERTOWN, MA—Enanta Pharmaceuticals Inc. (NASDAQ:ENTA), a biotechnology company with a market capitalization of $183 million, recently disclosed that its Chief Medical (TASE:PMCN) Officer, Scott T. Rottinghaus, sold a portion of his holdings in the company. According to an SEC filing, Rottinghaus sold 866 shares of common stock on December 6, 2024, at a weighted-average price of $8.06 per share. The total value of the transaction amounted to $6,979.
The sale was conducted to cover withholding taxes related to the settlement of a restricted stock unit award granted on November 23, 2022. This transaction was not discretionary, as it was required under the terms of the stock award. Following this transaction, Rottinghaus holds 17,918 shares of Enanta Pharmaceuticals (NASDAQ:ENTA).
The shares were sold in multiple transactions, with prices ranging from $7.87 to $8.22. Rottinghaus has committed to providing detailed information about each transaction upon request.
Enanta Pharmaceuticals is a biotechnology company focused on developing small molecule drugs for viral infections and liver diseases.
In other recent news, Enanta Pharmaceuticals' fiscal fourth-quarter and full-year 2024 financial report showed royalty revenues of approximately $14.6 million from Mavyret in the hepatitis C virus (HCV) market, a figure that fell below Leerink Partners' and FactSet's estimates. Despite this, Leerink adjusted its price target for Enanta, raising it to $12.00 and maintaining a Market Perform rating. Meanwhile, Baird reduced its price target to $20 from $26 but kept an Outperform rating.
In the realm of drug development, Enanta is making strides with its RSVPEDs trial for zelicapavir and its EDP-323 respiratory syncytial virus (RSV) antiviral. The RSVPEDs trial results are expected in December, while EDP-323 has shown encouraging results in a Phase 2a study. Additionally, Enanta has nominated EPS-1421 as the development candidate for its KIT inhibitor program and introduced a new STAT6 inhibitor discovery program.
Analysts from JMP Securities and H.C. Wainwright have maintained their positive ratings for Enanta, with the latter emphasizing the company's proficiency in developing impactful antiviral therapies. The market is eagerly awaiting the results from the RSVPEDs study, which could potentially advance zelicapavir into a Phase 3 registration program. These are among the recent developments in Enanta Pharmaceuticals' ongoing efforts to address unmet medical needs in the treatment of respiratory infections.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.